- Home
- Daily Diary
- Asset Class
- Sector
- Latest
- Author
- Street Notes
- TheStreet
- Switch to
+2.06| Last Update: 05/21/13 - 4:00 PM EDT |
| Volume: 3,487,807 |
| YTD Performance: 22.54% |
| Open: $102.45 |
| Previous Close: $102.18 |
| 52 Week Range: $67.61 - $114.95 |
| Oustanding Shares: 749,976,556 |
| Market Cap: 79,220,023,610 |
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||
| Qtr (06/13) | Qtr (09/13) | FY (12/13) | FY (12/14) | |
|---|---|---|---|---|
| Average Estimate | $1.68 | $1.73 | $7.19 | $8.31 |
| Number of Analysts | 4 | 4 | 4 | 4 |
| High Estimate | $1.71 | $1.80 | $7.25 | $8.74 |
| Low Estimate | $1.65 | $1.70 | $7.16 | $7.80 |
| Prior Year | $1.82 | $1.67 | $6.45 | $7.19 |
| Growth Rate (Year over Year) | -7.83% | 3.44% | 11.51% | 15.47% |
I have always resolved it in a practical, but chicken, way.
Amgen upgraded at GoldmanAMGN was upgraded from Neutral to Buy, Goldman Sachs said. $130 price target. Company also added to the Conviction Buy List, as the company has mulitple potential catalysts.
Yet the market refuses -- and sentiment is anything but giddy, even at these heights.
Banks continued higher, basic materials outperformed.
It’s the only thing that explains today’s action.
Amgen estimates increased at UBSAMGN estimates were raised on improving operating expenses, despite the weak first quarter results, said UBS.